Los Angeles Capital Management LLC Purchases 22,155 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Los Angeles Capital Management LLC raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 43.2% in the 4th quarter, Holdings Channel reports. The firm owned 73,405 shares of the biotechnology company’s stock after acquiring an additional 22,155 shares during the period. Los Angeles Capital Management LLC’s holdings in United Therapeutics were worth $16,141,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Cambridge Investment Research Advisors Inc. grew its holdings in shares of United Therapeutics by 9.0% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 1,705 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 141 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its stake in shares of United Therapeutics by 125.2% during the third quarter. Robeco Institutional Asset Management B.V. now owns 87,048 shares of the biotechnology company’s stock valued at $19,662,000 after acquiring an additional 48,397 shares during the last quarter. Raymond James & Associates grew its stake in shares of United Therapeutics by 1.7% in the third quarter. Raymond James & Associates now owns 28,054 shares of the biotechnology company’s stock worth $6,337,000 after purchasing an additional 471 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in United Therapeutics by 48.8% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 2,345 shares of the biotechnology company’s stock valued at $530,000 after purchasing an additional 769 shares during the period. Finally, Advisor Partners II LLC raised its position in United Therapeutics by 7.7% during the 3rd quarter. Advisor Partners II LLC now owns 1,339 shares of the biotechnology company’s stock worth $302,000 after purchasing an additional 96 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Up 1.7 %

United Therapeutics stock traded up $4.27 during trading on Friday, hitting $262.40. 779,523 shares of the company were exchanged, compared to its average volume of 541,180. The company has a current ratio of 3.77, a quick ratio of 4.28 and a debt-to-equity ratio of 0.04. The business’s 50 day moving average is $236.86 and its 200 day moving average is $229.40. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $262.51. The company has a market capitalization of $11.64 billion, a P/E ratio of 12.41 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. During the same quarter in the prior year, the company posted $4.86 earnings per share. The firm’s revenue for the quarter was up 33.7% on a year-over-year basis. Analysts predict that United Therapeutics Co. will post 23.75 earnings per share for the current year.

Analysts Set New Price Targets

UTHR has been the subject of several analyst reports. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. SVB Leerink began coverage on shares of United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 price target on the stock. Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. The Goldman Sachs Group upped their target price on United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday. Finally, Oppenheimer boosted their price target on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $308.78.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,756.70. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $30,756.70. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the completion of the transaction, the executive vice president now owns 36,599 shares in the company, valued at $7,880,130.69. The disclosure for this sale can be found here. In the last 90 days, insiders sold 141,790 shares of company stock worth $33,572,685. Insiders own 12.50% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.